FOXO3a-ROS pathway is involved in androgen-induced proliferation of prostate cancer cell

Yan Tao\textsuperscript{1,2†}, Shanhui Liu\textsuperscript{1,2†}, Jianzhong Lu\textsuperscript{1,2}, Shengjun Fu\textsuperscript{1,2}, Lanlan Li\textsuperscript{1,2}, Jing Zhang\textsuperscript{1,2}, Zhiping Wang\textsuperscript{1,2*} and Mei Hong\textsuperscript{3,4,5*}

Abstract

Background: Although FOXO3a can inhibit the cell proliferation of prostate cancer, its relationship with reactive oxygen species (ROS) in prostate cancer (PCa) has not been reported.

Methods: We analyzed the correlation between the expression of FOXO3a and the antioxidant enzyme catalase in prostate cancer with the TCGA and GEPIA databases. We also constructed a PPI network of FOXO3a via the STRING database. The mRNA and protein expression of FOXO3a and catalase were detected by qRT-PCR or western blotting in LNCaP and 22RV1 cells treated with DHT, R1881, or Enzalutamide. The effects of FOXO3a on catalase expression were tested by over-expressing or knocking down FOXO3a in LNCaP cells. Furthermore, the catalase activity and ROS level were detected in LNCaP cells treated with DHT. Cell proliferation and ROS were also analyzed in LNCaP which was treated with antioxidant.

Results: Results showed that the catalase expression was down-regulated in prostate cancer. A positive correlation between FOXO3a and catalase existed. DHT treatment could significantly reduce FOXO3a and catalase expression at mRNA and protein level in LNCaP cells. Catalase expression partly depended on FOXO3a as over-expression and knockdown of FOXO3a could result in the expression change of catalase. DHT treatment was found to inhibit catalase activity and increase ROS level in prostate cancer cell. Our study also demonstrated that antioxidant treatment reduced DHT-induced proliferation and ROS production in prostate cancer cell.

Conclusions: We discovered a novel mechanism by which DHT promotes prostate cancer cell proliferation via suppressing catalase activity and activating ROS signaling via a FOXO3a dependent manner.

Keywords: Prostate cancer, FOXO3a, ROS, Catalase

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
leading to CRPC and identifying related molecular pathways are important for CRPC therapy.

Forkhead box O transcription factors (FOXO) regulate multiple cellular processes, including cell cycle arrest, cell death, DNA damage repair, stress resistance and metabolism [4]. Emerging evidence revealed FOXOs functions are arrested in prostate cancer. FOXOs may be a tumor suppressor in prostate cancer [5]. In PCA cells, numerous therapies could trigger cell growth arrest by suppressing the activity of FOXO3a (FOXO3) [6–8]. Studies have also shown that oxidative stress is associated with the progression of prostate cancer in an androgen-dependent manner or an androgen-independent manner [9]. Oxidative stress regulates multiple cellular processes, such as cell growth and apoptosis. FOXO3a was involved in antioxidative protection in cells via regulating the cell detoxification to reactive oxygen species (ROS) [10, 11]. However, whether the FOXO3a-ROS pathway plays an important role in the generation of oxidative stress and the progression in prostate cancer remains unknown. In the current study, we found that FOXO3a-ROS pathway was involved in the DHT inducing cell proliferation. DHT treatment could arrest the expression of FOXO3a and inhibit the activity of catalase, which in turn increased ROS levels of PCA cell.

Methods
Gene expression analysis
To analyze the gene expression of FOXO3a (FOXO3) and catalase (CAT) in prostate cancer and in adjacent tissue, the relevant expression values of the genes were downloaded from The Cancer Genome Atlas (TCGA, https://cancergenome.nih.gov/). 52 normal prostate tissue sample and 499 prostate tumor sample were contained in the database. Wilcoxon rank sum test was used to evaluate the expression of FOXO3 and CAT mRNA between prostate cancer tissues and unpaired tissues. Wilcoxon signed rank test was applied to evaluate the expression of FOXO3a and CAT mRNA between prostate cancer tissues and paired tissues. Immune infiltrates score was calculate with GSVA package. The relationship between immune infiltration and FOXO3a and CAT expression were estimated with Spearman correlation test.

Correlation analysis between FOXO3a and CAT
Herein, we used GEPIA (http://geopia.cancer-pku.cn/index.html) [12] to analyze the correlation between FOXO3a expression and catalase expression in PCA. The correlation module generated the expression scatter plots between a pair of user-defined genes in PCA, together with the estimated statistical significance and the spearman’s correlation. Besides, we construct the FOXO3a protein–protein interaction (PPI) network analysis with STRING (https://string-db.org/).

Cell culture and FOXO3a knockdown or over-expression
Human prostate cancer cell LNCaP and 22RV1 were obtained from the Chinese Academy of Sciences Cell Bank (Shanghai, China). Cells were cultured in the RPMI-1640 medium (HyClone) supplemented with 10% FBS (HyClone), 100 μl penicillin and 100 μg/ml streptomycin. LNCaP cell was also cultured in the RPMI-1640 with 10% charcoal-stripped fetal bovine serum (Biological Industries). All cell lines were cultured in an incubator with 5% CO2 at 37 °C. For silencing FOXO3a expression, cells were transiently transfected with 100 pmol of FOXO3a-specific siRNA and negative control siRNA (NC) which were designed and synthesized by GenePharma (Shanghai, China). Sequences of FOXO3a siRNAs were as follows: siRNA1 5′-GCUGUC UCCAGGACAAUATT-3′; siRNA2 5′-GCACAGAG UGGAUGAAGUTT-3′; negative control siRNA: sense 5′-UUCUGGAACGUGUCAGUTT-3′, antisense 5′-ACGUGACACGUUCCGAGATT-3′. Cells were using Lipofectamine 2000 transfection reagent (Invitrogen 11668-019) following the manufacturer’s protocol. To overexpress FOXO3a in prostate cancer cell line, we purchased FOXO3a vector and control vectors from GeneChem (Shanghai, China). The recombinant plasmid vector transfection was performed according to the protocol provided by the company. After incubating transfected cells for 6 h, the medium was replaced with fresh RPMI1640 medium containing 10% FBS. 24 h later, the transfected cells were stimulated with DHT or enzalutamide for 48 h. Cells were harvested for quantitative real-time-PCR (qRT-PCR) and western blotting to assess the gene expression of FOXO3a and catalase.

Cell proliferation assays
5 × 10³ cells/well in 100 μl RPMI1640 medium supplemented with 10% FBS were seeded into 96-well plates and incubated at 37 °C with 5% CO2 for 24 h. Then cells were stimulated with DHT (1, 10, 50 nM), R1881 (0.02, 0.1, 1 nM) (Sigma-Aldrich Chemicals) and Enzalutamide (40 μM, 60 μM) (Top Science, Shanghai, China), or DHT (10 nM) and the ROS scavenger Tiron (1 mM) (4,5-dihydroxy-1,3-benzenedisulfonic acid, disodium salt monohydrate; Sigma-Aldrich Chemicals) for another 48 h. The cell proliferation was measured by adding 10 μl CCK8 (DojinDo, Japan) into each well and incubating at 37 °C for 4 h. Absorbance at 450 nm wavelength was measured by multifunctional chemiluminescence detector (Berto, Germany).
RNA isolation and qRT-PCR

Total RNA was extracted with TRIzol reagent (Takara Biotechnology Co., Dalian, China), and reverse transcribed using the PrimeScript RT reagent kit (Takara, Dalian, China). The target genes were quantified by quantitative real-time PCR using the SYBR Premix Ex Taqkit (Takara, Dalian, China) in a real-time thermal cycler (Bio-Rad Laboratories, Inc., USA). All mRNA expression levels were normalized to the β-actin. The primer sequences used were: FOXO3a (forward: 5′-CTACGAGTGGAAGGTGGCATT-3′; Reverse: 5′-TCT TGCCAGTTCCCTCATTTC-3′); Catalase (forward: 5′-AGATGCAAGCAGCTGGAAGGA-3′; Reverse: 5′-CAC GGCGCCTACTGTAATAA-3′); PSA (forward: 5′-CTG TCAGAGCCTGCGGAG-3′; Reverse: 5′-CTGGTT CAATGCTGCCCCC-3′); TMPRSS2 (forward: 5′-TAT GAAACCTGAACACAGTG-3′; Reverse: 5′-GCTATA CAGCGTAAAGAAAC-3′); β-actin (forward: 5′-GCA CAGAGCCTGCGCCTT-3′; Reverse: 5′-GTTGTCGAC GACGACG-3′).

Immunoblotting

Prostate cancer cell lines stimulated in vitro as indicated above were lysed in the cell lysis buffer (Beyotime Biotechnology, China). The lysates were quantified with the bicinchoninic acid (BCA) kit (Beyotime Biotechnology, China). Then, the supernatants were subjected to 10% SDS-PAGE and then transferred to PVDF membranes (0.22 μm, Millipore) for detection of FOXO3a, catalase and β-actin. The blots were cut prior to hybridization with antibodies during blotting. Rabbit anti-FOXO3a (catalog no. 12829) was purchased from Cell Signaling Technology. Rabbit anti-catalase (catalog no. sc-50508) was from Santa Cruz Biotechnology. β-actin (TA-09) was from ZSGB-BIO (Beijing, China) and dye-labeled secondary antibody (IRDye800 or IRDye700) was from LI-COR. Band intensity was quantified using the Image Studio Software.

Catalase activity detection

Catalase activity was detected with a catalase analysis kit (Beyotime Biotechnology, China) according to the manufacturer’s instructions. Briefly, The cell lysates were treated with excess hydrogen peroxide for an indicated time, and then the remaining hydrogen peroxide (not decomposed by catalase) was coupled with a substrate that on treatment with peroxidase produced N-4-antipyryl-3-chloro-5-sulfonate-p-benzoquinonemonoimine, which has an absorption maximum at 520 nm and was quantified spectrophotometrically.

ROS detection

5 × 10^5 cells in 100 μl medium were seeded into 96-well plates per well and incubated at 37 °C with 5% CO₂ for 24 h. Then, cells were cultured with DHT (10 nM) or/and Tiron (1 mM) for another 48 h. After washed two times with RPMI1640 medium, cells were incubated with DCFH-DA (Sigma-Aldrich Chemicals) for 30 min at 37 °C. Finally, fluorescence intensity was measured at 485 nm for excitation and 535 nm for emission.

Statistical analysis

Data are presented as mean ± SEM. Statistical analysis was performed using two-tailed Student’s t-tests. Values of p < 0.05 were considered significant. Data analyses were performed using GraphPad Prism7.0.

Results

The mRNA expression levels of FOXO3a and catalase in prostate cancer

To determine the differences of FOXO3a and catalase expression in prostate cancer and normal tissues, the FOXO3a and catalase mRNA levels were analyzed with the RNA-seq data from TCGA database. Result showed that the catalase expression was significantly reduced in prostate cancer compared with normal tissues (Fig. 1C, D). Although the FOXO3a expression was lower in prostate cancer, there was no significant difference between prostate cancer and normal tissues (Fig. 1A, B). We also assessed the correlation between immune infiltrates and FOXO3a and catalase expression in prostate cancer. Results indicated that FOXO3a and catalase expression is correlated with Tcm, T helper cells, etc. (Fig. 1E, F).

The correlation between FOXO3a and catalase

To further explore the correlation between FOXO3a and catalase in PCa, we evaluated the correlation in the GEPIA database [13, 14]. As shown in Fig. 2A, the expression of FOXO3a was significantly positively correlated with catalase in PCa (p < 0.001). To studying the function of FOXO3a, a PPI network was constructed using the STRING database. A total of 40 FOXO3a-interacting proteins were included in the PPI network complex and the resulting PPI network contained 41 nodes (Fig. 2B). As shown in Fig. 2B, FOXO3a has an interaction with catalase (CAT).

DHT treatment down-regulated the expression of FOXO3a and catalase in the LNCaP cells

Previous studies have demonstrated that FOXO3a is down-regulated in prostate cancer [6]. To study whether FOXO3a and catalase are involved in the
DHT and R1881 inducing prostate cancer proliferation, LNCaP and 22RV1 cells were treated with different concentrations of DHT or R1881 and Enzalutamide for 48 h, and cell viability was evaluated by the CCK8 assay. As shown in Fig. 3A and Additional file 1: Fig. S1, a significant increase in the proliferation effect was detected in a dose-dependent manner after treatment with DHT or R1881. Enzalutamide (40 μM or 60 μM) could slightly reduce the proliferation of LNCaP and 22RV1 cells. DHT and R1881 could reverse the proliferation effect which induced by Enzalutamide (Additional file 1: Fig. S1 and Additional file 2: Fig. S2). Results showed that the mRNA and protein levels of FOXO3a and catalase were indeed significantly down-regulated after the treatment with DHT (10 nM) in the LNCaP cells (Fig. 3B, D). However, FOXO3a and catalase expression change were not observed in 22RV1 cells which was treated with DHT (Fig. 3C, D). As a positive control, PSA and TMPRSS2 were found significantly up-regulated after treatment with DHT in LNCaP and 22RV1 cells (Fig. 3B, C). Enzalutamide could decreased the expression of AR-activated genes (Fig. 3B, C).

**DHT inducing catalase expression change depends on FOXO3a**

To explore whether FOXO3a affected the expression of catalase in LNCaP cells, the recombinant plasmid vectors containing FOXO3a fragment were transfected into the LNCaP cells. We found that the expression of FOXO3a was increased significantly (p < 0.05) (Fig. 4A, C). Although DHT treatment decreased catalase expression in LNCaP cells, over-expression of FOXO3a can restore the expression of catalase (Fig. 4A, C).

To further investigate whether FOXO3a knockdown can suppress the expression of catalase, two FOXO3a siRNAs were transfected into LNCaP cells. We found that both of FOXO3a siRNAs reduced the elevated expression of FOXO3a by over-expression vector (Fig. 4B, C). In addition, FOXO3a siRNAs also decreased the elevated expression of catalase (Fig. 4B, C). These results indicate...
Fig. 2 The correlation between FOXO3a and catalase at the gene and protein levels. A Scatterplots of correlations between FOXO3a expression and catalase in PCa by GEPIA database. B The PPI network, which contained 41 nodes, was constructed using the STRING database. The target protein (FOXO3a and catalase) has been marked in red.
that FOXO3a plays a vital role in the DHT regulating catalase expression.

**DHT treatment suppressed the catalase activity in LNCaP cells**

To study the effect of DHT on the catalase activity, we tested the catalase activity in LNCaP cells which was treated with DHT (1nM, 10nM) for 48h. Compared with the control group, the catalase activity in DHT group (10nM) was significantly decreased (Fig. 5A). Then we investigated the involvement of ROS by adding DCFH-DA to detect ROS production. We found that the ROS in DHT group was increased by 80% compared with the control group ($p<0.001$) (Fig. 5B).

**ROS scavenger Tiron could inhibit DHT-induced LNCaP cells proliferation**

ROS production increased in DHT-induced LNCaP cells proliferation. Whether DHT-induced cell proliferation depends on ROS production remains unknown. Herein, we used the ROS scavenger Tiron (1mM) to culture LNCaP cells. We found that Tiron treatment reduced DHT-induced proliferation (Fig. 6A) and ROS production ($p<0.05$) (Fig. 6B). This data further suggested that DHT promotes cell proliferation by reducing the expression of catalase and increasing ROS production. Besides, ROS production in the Tiron treatment group also decreased, indicating that Tiron could eliminate intracellular ROS and reduce the prostate cancer cell proliferation.

**Discussion**

FOXO3a is a member of the FOXO subfamily of forkhead transcription factors. It can induce most of the cellular processes, such as cell apoptosis, cell proliferation, cell cycle progression, DNA damage, and tumorigenesis. The post-transcriptional inhibition of microRNAs (miRNAs), PTMs and protein–protein interaction can regulate the function of FOXO3a [4].

In this study, we identified a novel mechanism that FOXO3a expression decreasing promotes prostate cancer cell proliferation by activating ROS signaling. Our results also demonstrated that DHT treatment promoted...
cell proliferation via inhibiting the expression of FOXO3a and arresting the catalase activity, which leads to the ROS production increasing in PCa cell.

Several studies have already reported that FOXO3a was decreased in human prostate cancer and they found deregulation of FOXO3a could promote prostate cancer progression [5, 9, 15, 16]. Consistent with previous study, our result also demonstrated that DHT or R1881 treatment promoted the proliferation of LNCaP and 22RV1 cells in a dose-dependent manner, and down-regulated the expression of FOXO3a in LNCaP cells. The expression of FOXO3a decreased in an androgen dependent manner in LNCaP cells. These results indicated that FOXO3a played a major role in the PCA cells. Benefiting from the TCGA dataset, we found that catalase expression was reduced in PCA. Through the GEPIA database, a positive correlation was found between FOXO3a and catalase. A protein–protein interaction also found

Fig. 4 The effect of over-expression of FOXO3a and knockdown of FOXO3a on the catalase expression in LNCaP cells. A Over-expression of FOXO3a increased the expression of FOXO3a and catalase after DHT treatment in LNCaP cells. B, C FOXO3a siRNAs transfection can decrease the elevated expression of FOXO3a and catalase at mRNA and protein level after DHT treatment and over-expression of FOXO3a. Control OE, over-expressing control vector; FOXO3a OE, FOXO3a over-expressing vector; NC, negative control siRNA; siRNA1, first FOXO3a-specific siRNA; siRNA2, second FOXO3a-specific siRNA. (*p < 0.05, **p < 0.01, ***p < 0.001)
between FOXO3a and catalase in the STRING database. Indeed, our study showed that catalase expression was strongly affected by FOXO3a. It consisted with previous study that FOXO3a can bind to the ATAAATA sequence in catalase promoter and then positively regulated catalase expression in rat cell [4, 17, 18]. Consequently, silencing FOXO3a reduce in the catalase mRNA and protein production in rat cardiomyocytes [17, 18]. In addition, our data showed that the mRNA and protein levels of FOXO3a and catalase were significantly decreased in the LNCaP cells after DHT treatment. Ectopic expression and silencing of FOXO3a further suggested that FOXO3a played a regulatory role on the upstream of catalase.

Catalase was encoded by CAT gene, and is a key enzyme in the metabolism of H₂O₂ and ROS [19]. The expression of catalase is various in human tumors [19–21]. It suggested that different types of cancer cells may showed different sensibility to oxidative stress. We investigated the catalase activity in prostate cancer cell under DHT treatment. Compared to the control group, the catalase activity in the DHT treatment group was significantly reduced. Furthermore, we found that the ROS level in the DHT treatment group was increased compared with control group. Increased ROS production has been observed in various cancers and shows several roles in the cell progress, for example, it could
activate pro-tumor signals, and then enhance the cell survival and proliferation [22, 23]. Our observation indicated that the increased ROS by DHT treatment induced the prostate cancer cell proliferation. Some researchers also reported that ROS was involved in the anti-tumor signals by initiating oxidative stress-induced cancer cells death [22–24]. Therefore, it is critical for cancer cells to maintain ROS homeostasis. Intervening ROS homeostasis maybe a promising method for cancer therapy.

Antioxidants showed an vital role in suppressing the activities of ROS [25]. Catalase is one of the endogenous antioxidants [26]. When the endogenous antioxidant system is inactive, reducing the excessive production of ROS depends on exogenous antioxidants, such as Tiron which is one of the ROS scavenger and it could promote cell survival by inhibiting the releasing of cytochrome c, caspase-3 activity [27]. In our study, Tiron reduced the DHT-induced proliferation and ROS production. In summary, our data suggested that DHT promoted cell proliferation by reducing the expression of catalase and then increasing ROS in prostate cancer cell. Tiron could reduce the intracellular ROS and then inhibit the DHT-induced cell proliferation. It was further demonstrated that antioxidant played an important role in cancer chemoprevention by suppressing oxidative stress-induced cell survival.

Conclusions
Above all, results shown here revealed the mechanisms by which DHT promoted PCa cell proliferation was that FOXO3a suppressed catalase expression and activated ROS signaling.

Abbreviations
PCa: Prostate cancer; ROS: Reactive oxygen species; FOXO: Forkhead box O transcription factors; GEPIA: Gene expression profiling interactive analysis; TCGA: The Cancer Genome Atlas; PPI: Protein-protein interaction; DHT: Dihydrotestosterone; DCFH-DA: Dichloro-dihydro-fluorescein diacetate; CRPC: Castration-resistant prostate cancer; qRT-PCR: Quantitative real-time-PCR; PTMs: Post-translational modifications.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12894-022-01020-9.

Additional file 1. Fig. S1. The effect of R1881 and Enzalutamide (ENZ) on the proliferation of LNCaP cells by CCK8 assay (450 nm).

Additional file 2. Fig. S2. Enzalutamide (40 μM or 60 μM) could slightly reduce the proliferation of LNCaP and 22RV1 cells by CCK8 assay (450 nm).

Acknowledgements
Not applicable.

Author contributions
HM and WZ conceived the research. TY, LS, LJ, FS and ZJ performed the experiments. LL and LS analyzed the data. TY wrote the original draft of the manuscript. HM and LS reviewed and edited the manuscript. WZ supervised the study. All authors read and approved the final manuscript.

Funding
This work was partially supported by the National Natural Science Foundation of China (No. 81302240), the Cuying Scientific and Technological Innovation Program of Lanzhou University Second Hospital (No. CY2019-QN05, CY2018-QN13), the Fundamental Research Funds for the Central Universities of Lanzhou University (No. Iuzjkpy-2021-kb29), the Gansu Natural Science Research (No. 20JR5RA319, 20JR10RA754, 21JR7RA419), and Gansu Province Higher Education Innovation Fund Project (No. 2020B-032, 2020B-035).

Availability of data and materials
All data analysed during this study are included in this published article. Generated data from each experimental repeat are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Key Laboratory of Urological Disease in Gansu Province, Lanzhou University Second Hospital, No. 82 Cuiyijingmen, Lanzhou 730030, Gansu, China. 2 Institute of Gansu Nephron-Urological Clinical Center, Lanzhou University Second Hospital, Lanzhou, Gansu, China. 3 State Key Laboratory of Chemical Oncogenomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Nanhan District, Shenzhen 518055, Guangdong, China. 4 Key Laboratory of Chemical Genomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, Guangdong, China. 5 Drug Discovery Center, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, Guangdong, China.

Received: 12 August 2021   Accepted: 12 April 2022
Published online: 29 April 2022

References
1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
2. Klukovich R, Nilsson E, Sadler-Riggleman I, et al. Environmental toxicant induced epigenetic transgenerational inheritance of prostate pathology and stromal-epithelial cell epigenome and transcriptome alterations: ancestral origins of prostate disease. Sci Rep. 2019;9(1):2209.
3. Conford P, van den Bergh RCN, Briers E, et al. EAU-ESMO-ESTRO-SIOG guidelines on prostate cancer: Part II—2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2021;79(2):263–82.
4. Liu Y, Ao X, Ding W, et al. Critical role of FOXO3a in carcinogenesis. Mol Cancer. 2018;17(1):104.
5. Li R, Quan Y, Xia W. SIRT3 inhibits prostate cancer metastasis through regulation of FOXO3A by suppressing Wnt/beta-catenin pathway. Exp Cell Res. 2018;364(2):143–51.
6. Shan Z, Li Y, Yu S, et al. CTCF regulates the Foxo3a signaling pathway to affect the progression of prostate cancer. J Cell Mol Med. 2019;23(5):3130–9.
7. Lu Z, Zhou R, Kong Y, et al. S-equol, a secondary metabolite of natural anticancer isoflavone daidzein, inhibits prostate cancer growth in vitro.
8. Oak C, Khalifa AO, Isali I, et al. Diosmetin suppresses human prostate cancer cell proliferation through the induction of apoptosis and cell cycle arrest. Int J OncoL 2018;53(2):835–43.

9. Habrowska-Gorczynska DE, Koziel MJ, Kowalska K, et al. FOXO3a and its regulators in prostate cancer. Int J Mol Sci. 2021;22(22):12530.

10. Fasano C, Disciglio V, Bertora S, et al. FOXO3a from the nucleus to the mitochondria: a round trip in cellular stress response. Cells. 2019;8(9):1110.

11. Brown AK, Webb AE. Regulation of FOXO factors in mammalian cells. Curr Top Dev Biol. 2018;127:165–92.

12. Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–102.

13. Mukaka MM. Statistics corner: a guide to appropriate use of correlation coefficient in medical research. Malawi Med J. 2012;24(3):69–71.

14. Tang Z, Kang B, Li C, et al. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556–60.

15. Shukla S, Bhaskaran N, Maclennan GT, et al. Deregulation of FoxO3a accelerates prostate cancer progression in TRAMP mice. Prostate. 2013;73(14):1507–17.

16. Shukla S, Shukla M, MacLennan GT, et al. Deregulation of FOXO3A during prostate cancer progression. Int J OncoL. 2009;34(6):1613–20.

17. Tan WQ, Wang K, Lv DY, et al. Foxo3a inhibits cardiomyocyte hypertrophy through transactivating catalase. J Biol Chem. 2008;283(44):29730–9.

18. Glorieux C, Zamocky M, Sandoval JM, et al. Regulation of catalase expression in healthy and cancerous cells. Free Radic Biol Med. 2015;87:84–97.

19. Glorieux C, Calderon PB. Catalase, a remarkable enzyme: targeting the oldest antioxidant enzyme to find a new cancer treatment approach. Biol Chem. 2017;398(10):1095–108.

20. Galasso M, Gambino S, Romanelli MG, et al. Browsing the oldest antioxidant enzyme: catalase and its multiple regulation in cancer. Free Radic Biol Med. 2021;172:264–72.

21. Glorieux C, Sandoval JM, Dejeans N, et al. Evaluation of potential mechanisms controlling the catalase expression in breast cancer cells. Oxid Med Cell Longev. 2018;2018:5351967.

22. Moloney JN, Cotter TG. ROS signalling in the biology of cancer. Semin Cell Dev Biol. 2018;80:50–64.

23. Prasad S, Gupta SC, Tyagi AK. Reactive oxygen species (ROS) and cancer: role of antioxidative nutraceuticals. Cancer Lett. 2017;367:95–105.

24. Reczek CR, Chandel NS. ROS promotes cancer cell survival through calcium signaling. Cancer Cell. 2018;33(6):949–51.

25. Dastmalchi N, Baradaran B, Latifi-Navid S, et al. Antioxidants with two faces toward cancer. Life Sci. 2020;258:11818.

26. He L, He T, Farrar S, et al. Antioxidants maintain cellular redox homeostasis by elimination of reactive oxygen species. Cell Physiol Biochem. 2017;44(2):532–53.

27. Chen L, Li G, Peng F, et al. The induction of autophagy against mitochondria-mediated apoptosis in lung cancer cells by a ruthenium (II) imidazole complex. Oncotarget. 2016;7(49):80716–34.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.